Article Link: FDA Approves Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphobl...
FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Article Link: FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN, June 30, 2021 /PRNe...
FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis
Article Link: FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis EMERYVILLE, Calif...
FDA Approves Pradaxa (dabigatran) as First Oral Blood Thinning Medication for Children
Article Link: FDA Approves Pradaxa (dabigatran) as First Oral Blood Thinning Medication for Children June 21, 2021 — Today, the U.S...
FDA Approves Soaanz (torsemide) for Edema Treatment in Patients with Heart Failure and Renal Disease
Article Link: FDA Approves Soaanz (torsemide) for Edema Treatment in Patients with Heart Failure and Renal Disease VIENNA, VA. (PRWEB) JU...
FDA Approves Astepro Allergy (azelastine) Nasal Spray for Over-the-Counter Use
Article Link: FDA Approves Astepro Allergy (azelastine) Nasal Spray for Over-the-Counter Use WHIPPANY, N.J.–(BUSINESS WIRE) June 17...
FDA Approves Blueprint Medicines' Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
Article Link: FDA Approves Blueprint Medicines’ Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis ...
FDA Approves Rezipres (ephedrine hydrochloride injection) for Hypotension During Anesthesia
Article Link: FDA Approves Rezipres (ephedrine hydrochloride injection) for Hypotension During Anesthesia DEER PARK, Ill., June 15, 2021 ...
U.S. Food and Drug Administration Approves New Formulation of Epclusa, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
Article Link: U.S. Food and Drug Administration Approves New Formulation of Epclusa, Expanding Pediatric Indication to Treat Children Ages 3 and Older...
Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
Article Link: Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6...
